Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Roxadustat meets primary endpoints in two phase III anemia trials in China

Jan. 31, 2017

Exemplar Genetics contracted to create models of sickle cell disease

Jan. 27, 2017

Bayer Pharma describes coagulation factor XIa and kallikrein B inhibitors

Jan. 24, 2017

Global Blood Therapeutics begins enrollment in phase III study of GBT-440

Jan. 19, 2017

CRISPR Cas9 gene repair strategy shows promise for treatment of X-CGD

Jan. 13, 2017

Phase II results for crizanlizumab as prevention of pain crises in patients with sickle cell disease

Jan. 10, 2017

Afstyla approved in E.U. for hemophilia A

Jan. 10, 2017

FDA clears Sangamo's IND for hemophilia A gene therapy

Jan. 10, 2017

FDA accepts for review BLA for LFB's eptacog beta for hemophilia

Jan. 9, 2017

Alexion Pharmaceuticals' ALXN-1210 awarded FDA orphan status for PNH

Jan. 9, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...